Microbiome Dysfunction in Surgical Intensive Care Unit Survivors

June 9, 2025 updated by: University of Florida

Microbiome Dysfunction in Surgical Intensive Care Unit Survivors Subtitle: The Role of Brain-Bone Marrow-Gut Interaction Following Major Trauma Pathological Myeloid Activation After Sepsis and Trauma

Oral and gastrointestinal microbiome dysfunction has been demonstrated to be a culprit of various systemic dysfunctions in peripheries such as cardiovascular, nervous, endocrine and musculoskeletal systems. The topic of microbiome dysfunction after surgical intensive care admission is understudied but may be responsible for persistent systemic inflammation clinically observed in surgical intensive care patients. Therefore, the objective of this project is to investigate the oral and gut microbiome after the acute phase of sepsis, severe trauma injury, cardiopulmonary bypass, and major vascular surgery to compare with 108 age-matched healthy population controls

Study Overview

Status

Recruiting

Intervention / Treatment

Detailed Description

The investigators hypothesize that alterations of the oral and gut microbiota will correlate with persistent systemic inflammation in surgical intensive care unit survivors compared to existing healthy population controls. This research group will collect oral and stool samples from 108 sepsis survivors, 108 trauma survivors, 108 cardiopulmonary bypass survivors, and major vascular surgery survivors (groups of ages 18-45, 46-64, and >65; male and female; n=18 per age + sex cohort) admitted to the surgical intensive care unit between day 7 and 28 of hospital admission, as well as 3 and 6 months after their intensive care unit hospitalization. The investigators will perform 16S rRNA DNA sequencing on the isolated bacterial DNA from these samples and bioinformatic analysis to determine microbiota alterations between time points and between surgical ICU survivor cohorts and a control cohort. In addition, the investigators will draw 20ml of blood to isolate plasma.

Trauma Subgroup for traumatic brain injury (TBI) pilot study: Our team will enroll 15 additional trauma injury patients with traumatic brain injury. This subgroup will have an added stool (if available) and blood sample collection after initial injury (+ 5 days). The additional sample will be compared to the sample collected at 14-21 days and follow up samples at 3 and 6 months. The results will be associated with Glasgow Outcome Scale Extended at 3 and 12 month time points and the recorded discharge Rancho Los Amigos scale score from the medical record. The specific aims will be: Aim 1 - define the impact of persistent systemic inflammation on the gastrointestinal microbiota in sepsis and trauma survivors and Aim 2 - identify microbial genes associated with persistent systemic inflammation in sepsis and trauma survivors compared to normal controls. Trauma Subgroup Aim: Pilot study to test the hypothesis that changes in the microbiome towards pathogenic microbe is associated with worsened outcomes in trauma injury patients with TBI (traumatic brain injury).

Study Type

Observational

Enrollment (Estimated)

468

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Florida
      • Gainesville, Florida, United States, 32610
        • Recruiting
        • UF Health at Shands hospital
        • Contact:
        • Contact:
          • Jennifer Lanz, MSN
          • Phone Number: 352-273-5497
        • Principal Investigator:
          • Philip Efron, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 110 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Probability Sample

Study Population

Patients admitted to surgical intensive care units who screen positive for sepsis, have severe trauma injury, undergo cardiopulmonary bypass or major vascular surger and are being treated by our standard-of care ICU protocols are candidates for the study. Healthy adult volunteers will provide reference control samples.

Description

Sepsis Population

Inclusion Criteria

  1. Admission to the 46, 77, 87, 4 East, 4 West, or 24-5 ICUs where clinical care can be managed by the critical care organization guided by standard operating procedures.
  2. Age ≥18 years
  3. Meets Sepsis 3 criteria at time of sepsis diagnosis
  4. Has remained in ICU for 14 days (+/- 7 days) following sepsis diagnosis.
  5. Ability to obtain patient/LAR informed consent.
  6. Is receiving adequate nutritional intake: oral or enteral nutrition.

Exclusion Criteria

  1. Severe traumatic brain injury with unencumbered assessment of GCS equaling 3 on admission to intensive care unit
  2. Refractory shock (i.e., patients who are expected to die within 12 hours).
  3. Uncontrollable source of sepsis (e.g. irreversible disease state such as unresectable dead bowel).
  4. Patient or patient's family are not committed to aggressive management of the patient's condition.
  5. Known HIV infection with CD4 count <200 cells/mm3.
  6. Organ transplant recipient on immunosuppressive agents.
  7. Known pregnancy.
  8. Prisoners.
  9. Institutionalized patients j Inability to obtain informed consent.

k) Burn injury greater than 20% TBSA (total body surface area)

Trauma Population

Inclusion Criteria

1. All adults (age ≥18 to 54) require both:

a. Blunt and/or penetrating trauma patient with i. Hemorrhagic shock defined by:

1. Systolic BP (SBP) ≤ 90 mmHg or 2. Mean arterial pressure ≤ 65 mmHg or 3. Base deficit (BD) ≥5 meq or 4. Lactate ≥ 2 or 5. Active red blood cell or whole blood transfusion within 6 hours of arrival

b. Injury Severity Score (ISS) greater than or equal to 15

2. All adults (age 55 and older) require:

a. Either hemorrhagic shock defined by: i. Systolic BP (SBP) ≤ 90 mmHg or ii. Mean arterial pressure ≤ 65 mmHg or iii. Base deficit (BD) ≥5 meq or iv. Lactate ≥ 2 or v. Active red blood cell or whole blood transfusion within 6 hours of arrival

OR

b. Injury Severity Score (ISS) greater than or equal to 15. 3. Ability to obtain Informed Consent

Exclusion Criteria

  1. Patients not expected to survive greater than 48 hours.
  2. Prisoners.
  3. Pregnancy.
  4. Previous bone marrow transplantation.
  5. Patients with End Stage Renal Disease.
  6. Patients with any pre-existing hematological disease (e.g. hemochromatosis, myelodysplastic syndrome, hematologic cancers)
  7. Burn injury greater than 20% TBSA
  8. Severe traumatic brain injury with unencumbered assessment of GCS equaling 3 on admission to intensive care unit.

Trauma TBI subgroup (15 participants)

Inclusion criteria will be:

1. Any adult age 18 or older with any traumatic bleed (intracerebral hemorrhage, subarachnoid hemorrhage, intraparenchymal hemorrhage, subdural hematoma, cerebral epidural hematoma) and any GCS (Glasgow Coma Score).

Exclusion criteria is the same used for the trauma cohort.

Cardiac-Surgery operation:

Inclusion Criteria:

  1. Adult (>18 years age) patients undergoing open cardiac surgery
  2. Ability to obtain patient informed consent
  3. was placed on cardiopulmonary bypass at their initial operation at UF Health

Exclusion Criteria:

  1. Inability to obtain informed consent,
  2. Pregnancy
  3. Evidence of multi-organ failure on presentation
  4. Patients with any pre-existing hematological disease (e.g. hemochromatosis, myelodysplastic syndrome, hematologic cancers
  5. Prisoners
  6. Previous bone marrow transplantation
  7. Burn injury greater than 20% TBSA

Open abdominal vascular operation:

Inclusion Criteria:

  1. Adult (>18 years age) patients undergoing open abdominal vascular surgery
  2. Ability to obtain patient informed consent,

Exclusion Criteria:

  1. Inability to obtain informed consent,
  2. Pregnancy
  3. Evidence of multi-organ failure on presentation
  4. Patients with any pre-existing hematological disease (e.g. hemochromatosis, myelodysplastic syndrome, hematologic cancers
  5. Prisoners
  6. Previous bone marrow transplantation.
  7. Burn injury greater than 20% TBSA

Healthy Control

Inclusion criteria will be:

  1. All adults (age ≥18)
  2. Ability to obtain Informed Consent prior to blood collection.

Exclusion Criteria will be:

  1. Current, chronic steroid use
  2. Pregnancy
  3. Current or recent (within 7 days) use of antibiotics.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Sepsis Survivors

Oral swab, saliva, and feces collected between 7 to 28 days of hospital admission and at 3 and 6 months post hospitalization. Telephone call at 12 months.

Blood will be collected at time of first feces collection

Oral swab and saliva, human feces collection and blood sampling
Other Names:
  • Blood sampling
  • Oral swab and saliva
Healthy Control Population
One time collection of oral swab and saliva, feces, and blood upon enrollment used for comparison to identify microbial genes associated with persistent systemic inflammation in sepsis survivors.
Oral swab and saliva, human feces collection and blood sampling
Other Names:
  • Blood sampling
  • Oral swab and saliva
Trauma Survivor

Oral swab, saliva, and feces collected between 7 to 28 days of hospital admission and at 3 and 6 months post hospitalization. Telephone call at 12 months.

Blood will be collected at time of first feces collection

Oral swab and saliva, human feces collection and blood sampling
Other Names:
  • Blood sampling
  • Oral swab and saliva
Traumatic Brain Injury (TBI)

Oral swab, saliva, and feces collected at admission (day 1(+5)) and between 7 to 28 days of hospital admission and at 3 and 6 months post hospitalization. Telephone call at 12 months.

Blood will be collected at time of first and second feces collection.

Oral swab and saliva, human feces collection and blood sampling
Other Names:
  • Blood sampling
  • Oral swab and saliva
Cardiopulmonary Bypass

Oral swab, saliva, and feces collected between 7 to 28 days of hospital admission and at 3 and 6 months post hospitalization. Telephone call at 12 months.

Blood will be collected at time of first feces collection

Oral swab and saliva, human feces collection and blood sampling
Other Names:
  • Blood sampling
  • Oral swab and saliva
Major Vascular Surgery

Oral swab, saliva, and feces collected between 7 to 28 days of hospital admission and at 3 and 6 months post hospitalization. Telephone call at 12 months.

Blood will be collected at time of first feces collection

Oral swab and saliva, human feces collection and blood sampling
Other Names:
  • Blood sampling
  • Oral swab and saliva

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Determine the impact of persistent systemic inflammation on oral and gastrointestinal microbiota in surgical ICU survivors & identify microbial genes associated with persistent systemic inflammation of surgical ICU survivors compared to normal controls.
Time Frame: through study completion, an average of 6 months
Identify oral and gut microbiome dysfunction through Microbial Taxonomic Analysis and Meta-transcriptomic Analysis
through study completion, an average of 6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Philip Efron, MD, UF COM Department of Surgery

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 21, 2022

Primary Completion (Estimated)

May 31, 2027

Study Completion (Estimated)

May 31, 2028

Study Registration Dates

First Submitted

April 12, 2022

First Submitted That Met QC Criteria

April 26, 2022

First Posted (Actual)

May 2, 2022

Study Record Updates

Last Update Posted (Actual)

June 12, 2025

Last Update Submitted That Met QC Criteria

June 9, 2025

Last Verified

June 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • IRB202102863
  • R35GM140806 (U.S. NIH Grant/Contract)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Sepsis, Trauma Injury

Clinical Trials on Human feces collection

Subscribe